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Abstract: Arterial hypertension is one of the major diseases in the Western world. It is an 
independent cardiovascular risk factor and is associated with increased morbidity and mortality. 
Several drug classes have been shown to be effective in the treatment of hypertension. Aliskiren 
is a direct renin inhibitor and belongs to the class of renin-angiotensin-aldosterone system 
inhibitors. Several large studies have shown that aliskiren is effective in lowering blood pres-
sure, and equivalent in this respect to the angiotensin-converting enzyme (ACE) inhibitors and 
the angiotensin receptor-1 blockers (ARBs). Furthermore, aliskiren has a safety and tolerability 
profile comparable with that of the ARBs and slightly better than that of the ACE inhibitors. 
From a pathophysiologic perspective, it can be combined with hydrochlorothiazide success-
fully, because it can block the diuretic-induced increase in plasma renin activity. Its combina-
tion with hydrochlorothiazide in a single pill has been investigated and shown to be superior 
to monotherapy with respect to blood pressure control and improvement in patient compliance 
with therapy. Further studies are needed to show whether aliskiren and its combination with 
hydrochlorothiazide is effective in preventing cardiovascular events and mortality when end 
organ damage is present.
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Introduction
Arterial hypertension is one of the most common diseases in the developed world. 
It is one of the major cardiovascular risk factors for development of coronary heart 
disease, heart failure, stroke, and chronic kidney disease. In 2000, more than 970 million 
people worldwide had elevated blood pressure, and this number is expected to have 
increased by 60% in 2025.1 According to the World Health Organization, arterial 
hypertension accounts for 7.1 million deaths per year, and this number is expected 
to rise in the future.2
The guidelines of the 7th Joint National Committee on Prevention, Detection, 
Evaluation and Treatment of High Blood Pressure (JNC 7), as well as those of the 
European Society of Cardiology and European Society of Hypertension recommend 
a target blood pressure lower than 140/90 mmHg in uncomplicated hypertension and 
lower than 130/80 mmHg when additional risk factors, such as diabetes or coronary 
heart disease, are present.3,4 Despite these recommendations and the existence of many 
different antihypertensive drugs, hypertension in the US is only controlled in about 
30%–60% of patients, and this rate is much lower in western European countries.5,6 
At least 75% of hypertensive patients require combination therapy to achieve current 
blood pressure goals.7–9 Combination of several agents allows for synergistic action Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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and use of lower doses of the individual drugs, leading 
to a reduction in side effects and improvement of patient 
compliance.10 Therefore, combination treatment as first-line 
therapy is a logical choice for patients with moderate to 
severe hypertension.
The renin-angiotensin-aldosterone system (RAAS) plays 
a crucial role in the pathophysiology of hypertension and 
cardiovascular diseases.11 Drugs that target the RAAS, such 
as angiotensin-converting enzyme (ACE) inhibitors and 
blockers of angiotensin receptor-1 (ARBs), are effective in 
reducing blood pressure, as well as the morbidity and mortal-
ity associated with hypertension and cardiovascular diseases. 
Their low rate of side effects makes them well tolerated and 
therefore attractive as first-line agents in the treatment of arte-
rial hypertension.12 Blockers of the RAAS are widely com-
bined with thiazide diuretics, mainly hydrochlorothiazide, a 
strategy supported pathophysiologically by the mechanism 
of action of the two drug classes. Hydrochlorothiazide leads 
to activation of the RAAS through sodium and water deple-
tion, which limits its antihypertensive effects (Table 1), and 
its combination with a RAAS blocker potentiates the effects 
of both agents.13
A recent addition to the family of RAAS-blockers is 
aliskiren, a direct renin inhibitor, now approved for the 
treatment of hypertension. Several studies have already 
investigated the effects of aliskiren as monotherapy in low-
ering blood pressure and in combination with other agents, 
including calcium channel blockers and hydrochlorothiazide. 
At present, aliskiren is available as a fixed combination 
with hydrochlorothiazide in several dose strengths, ie, 
150/12.5 mg, 150/25 mg, 300/12.5 mg, and 300/25 mg, and 
is approved as second-line treatment in patients whose blood 
pressure is not adequately controlled by the individual drugs 
alone. This review focuses on the efficacy of the combination 
of aliskiren with hydrochlorothiazide as a potential first-line 
treatment of hypertension.
Renin-angiotensin-aldosterone 
inhibitors
The RAAS is a system of active peptides and enzymes, 
mainly responsible for fluid and electrolyte homeostasis 
and vascular tone (see Figure 1). Furthermore, RAAS 
plays an important role in inflammation, cellular and organ 
hypertrophy, and   fibrosis, and activation of this system is 
therefore important in the pathophysiology of cardiovascular 
diseases, including hypertension, myocardial infarction, heart 
and kidney failure, and stroke.14,15
The RAAS cascade begins with renin, an aspartyl pro-
tease released by the juxtaglomerular cells of the kidney into 
the circulation, which consists of two homologous lobes with 
a cleft in between containing two catalytic aspartic residues.16 
Renin is produced by proteolytic transformation of its proen-
zyme, prorenin.17 Renin acts on angiotensinogen and converts 
it to angiotensin I. This is the rate-limiting step of RAAS 
activation. Angiotensin I is converted to angiotensin II in the 
lungs through the action of ACE. Traditionally, angiotensin II 
is considered to be the major effector molecule of the RAAS. 
Angiotensin II exerts its effects mainly through its Type 1 
(AT1) receptors in target organs, but several other types of 
receptors exist, the actions of which are as yet not entirely 
clear.18 Angiotensin II also acts on the adrenal cortex, leading 
to the release of aldosterone into the circulation.
Blockade of the RAAS using ACE inhibitors and AT1 
receptor blockers has been the mainstay of medical treatment 
for cardiovascular disease for the last two to three decades. 
ACE inhibitors inhibit the action of ACE and disrupt the 
conversion of angiotensin I into angiotensin II. ARBs act on 
AT1 receptors and directly block the actions of angiotensin II 
on target organs. RAAS inhibition using ACE inhibitors or 
ARBs has been proven to be effective in reducing elevated 
blood pressure, preventing and slowing the progression of 
cardiovascular disease, and reducing the associated   morbidity 
and mortality.19
Table 1 effects of RAAS blockers and common antihypertensive agents on different RAAS components
Agent PRC PRA Angiotensinogen Angiotensin I Angiotensin II Angiotensin 1–7 Aldosterone
β-blockers ↓ ↓ – ↓ ↓ ↓ ↓
Calcium antagonists ↑ ↑ ↓ ↑ ↑ ↑ ↑
Diuretics ↑ ↑ ↓ ↑ ↑ ↑ ↑
ACei ↑ ↑ ↓ ↑ ↓ ↑ ↓
ARBs ↑ ↑ ↓ ↑ ↑ ↑ ↓
Aliskiren ↑↑ ↓ – ↓ ↓ ↓ ↓
Aliskiren-HCTZ ↑↑↑ ↓ – ↓ ↓ ↓ ↓
Abbreviations:  ACei,  angiotensin-converting-enzyme  inhibitors;  ARB,  angiotensin  receptor  blocker;  HCTZ,  hydrochlorothiazide;  PRC,  plasma  renin  concentration;   
PRA, plasma renin activity; RAAS, renin-angiotensin-aldosterone system.Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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However, after some months of treatment with ACE 
  inhibitors, levels of angiotensin II in the blood start to 
rise again, which is known as the “angiotensin escape 
phenomenon”.20 Furthermore, both ACE inhibitors and ARBs 
lead to a   compensatory increase in plasma renin concentration 
and plasma renin activity.21 An increase in plasma renin   activity 
may ultimately lead to increased angiotensin II   production, 
which, in turn, may act on receptors other than the AT1 receptor, 
with potentially harmful effects. However, the exact clinical 
importance of this phenomenon remains unknown.
Aliskiren is the latest member of the RAAS blocker class 
of drugs. It acts directly on renin and inhibits its action, 
thereby blocking the activation of RAAS and the production 
of angiotensin II directly at its rate-limiting step.22 Aliskiren 
binds the active site of renin and inhibits its catalytic activity. 
The action of aliskiren at this early upstream step has the 
potential to block the action of angiotensin more effectively 
than the other known RAAS blockers.
Aliskiren-hydrochlorothiazide: 
Pharmacokinetics and 
pharmacodynamics
Aliskiren is the first orally available direct nonpeptide renin 
inhibitor. Its bioavailability after oral administration is 2.6%, 
with a maximum plasma concentration reached within 
1–3 hours after a single oral dose.23 Steady-state plasma con-
centration is reached after 7–8 days of daily administration. 
Plasma concentration is linearly related to dose in the range 
of 40–640 mg/day. Its half-life in plasma is 23–40 hours, 
thus enabling single daily dosing.24 The majority (90.9%) of 
aliskiren is excreted via the biliary/fecal route in healthy sub-
jects after a single dose of 300 mg, while 0.6% of the drug is 
collected in the urine.25 No dose modification needs to be made 
in the presence of renal or liver disease, and the pharmacoki-
netics are similar in the common ethnic groups. Aliskiren is 
not metabolized by cytochrome P450, and therefore has few 
interactions with other drugs metabolized by this enzyme.
Aliskiren decreases blood pressure mainly by reduc-
ing angiotensin II levels. A study in healthy normotensive 
volunteers showed that aliskiren decreased plasma renin 
activity in a dose-dependent manner after a single oral dose 
in the 40–600 mg/day range. Angiotensin I and II decreased 
accordingly, while plasma renin concentration increased.26 
In another small study in 12 healthy mildly sodium-depleted 
volunteers, single oral doses of aliskiren 300 mg decreased 
plasma renin activity, as well as angiotensin I and II levels 
in the blood for 48 hours, and reduced urinary aldosterone 
excretion. Of note, this reduction was stronger and more 
durable than that of valsartan 160 mg. However, aliskiren 
also induced a greater increase in plasma renin concentra-
tion than valsartan.27 Increased plasma renin concentration 
occurs to a greater extent with aliskiren than with other 
ACE inhibitors and ARBs, and might be an important issue 
because prorenin and renin have been shown to stimulate the 
(pro)renin receptor and induce fibrosis, apoptosis, and organ 
hypertrophy in experimental disease models.28 However, the 
clinical significance of this finding remains unclear.
Plasma renin activity remains suppressed for up to one 
month after discontinuation of aliskiren, suggesting that the 
action of aliskiren may persist for far longer than the drug 
half-life. Interestingly, this effect is associated with lower 
blood pressure after discontinuation of the drug.29
The bioavailability of oral hydrochlorothiazide is high, 
ranging between 50% and 80%. It reaches its maximal 
blood concentration after 1.0–2.5 hours, and has a half-life 
of 6–19 hours. Hydrochlorothiazide is not metabolized, and 
95% is excreted in the urine.30
Hydrochlorothiazide induces activation of the RAAS 
mainly via sodium and water depletion, leading to increased 
plasma renin concentration and plasma renin activity, and 
therefore angiotensin II production.31 Increased plasma renin 
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Figure  1  Schematic  illustration  of  the  RAAS  and  the  sites  of  its  blocking  for 
existing RAAS blockers. Shown also are the alternative pathways, which are possibly 
activated through increase of the different components of the RAAS due to the 
actions of RAAS blocking agents (see also Table 1). Increased renin concentration 
in the blood can lead to stimulation of the (pro)renin receptor, which leads to 
intracellular activation of apoptosis, hypertrophy, and fibrosis pathways. Increase 
of angiotensin II and its metabolites leads to stimulation of alternative receptors 
which have different effects on vasoconstriction, endothelial function, hypertrophy, 
and inflammation.
Abbreviations: ACei, angiotensin-converting-enzyme inhibitor; ARB, angiotensin-
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concentration and plasma renin activity is further potentiated 
when hydrochlorothiazide is combined with an ACE inhibitor 
or ARB. However, aliskiren was able to suppress plasma renin 
activity when combined with hydrochlorothiazide 25 mg/day 
in a study of hypertensive obese patients.32 Interestingly, 
aliskiren also decreases plasma renin activity when combined 
with other agents known to increase plasma renin activity, 
including ACE inhibitors and ARBs.27
Use of aliskiren-hydrochlorothiazide 
in hypertension
Successful use of aliskiren as monotherapy in hyperten-
sion has been demonstrated in several studies, and has been 
extensively reviewed elsewhere.33–35 Doses of 150–300 mg 
once daily have been shown to have similar antihypertensive 
effects as comparable doses of ACE inhibitors and ARBs.35 
Interestingly, the antihypertensive effects of aliskiren lasted 
surprisingly longer than its half-life in blood and persisted for a 
month after discontinuation of the drug in a study by   Andersen 
et al.29 This observation is confirmed by a meta-analysis of 
eight studies showing that stopping treatment with aliskiren 
does not lead to a paradoxical increase in blood pressure.36
In a placebo-controlled study of 455 Japanese patients 
with hypertension and a mean sitting diastolic blood pres-
sure of 95–110 mmHg, aliskiren in doses of 75, 150, and 
300 mg lowered blood pressure in a dose-dependent   manner. 
Interestingly, after correcting for placebo, the reduction 
in systolic and diastolic blood pressure was 5.7/4 mmHg, 
5.9/4.5 mmHg, and 11.2/7.5 mmHg, respectively, indicating 
a rather small effect.37
Several other studies have compared different doses of 
aliskiren with the ARBs, irbesartan, losartan, and valsartan, as 
well as valsartan-hydrochlorothiazide and valsartan-aliskiren 
combinations.38–40 In all studies, aliskiren was effective in the 
lowering of blood pressure compared with placebo and to 
a similar extent with comparable doses of the ARBs tested. 
Furthermore, the combination of valsartan-aliskiren had a 
stronger antihypertensive effect than monotherapy, and was 
as effective as the valsartan-hydrochlorothiazide combina-
tion. These findings were confirmed in a meta-analysis show-
ing that aliskiren is as effective for blood pressure reduction 
as the ACE inhibitors and ARBs.35
Hydrochlorothiazide is the most commonly prescribed 
antihypertensive drug in the US, and remains the drug of 
choice for uncomplicated hypertension in the JNC 7 rec-
ommendations. However, the most commonly prescribed 
doses of hydrochlorothiazide are 12.5 and 25 mg. Surpris-
ingly, all the major studies were performed using higher 
  hydrochlorothiazide doses or hydrochlorothiazide in 
combination with other antihypertensive agents, so little or 
no evidence exists for the efficacy of low-dose hydrochloro-
thiazide in hypertension and cardiovascular disease. The Anti-
hypertensive and Lipid-Lowering Treatment to Prevent Heart 
Attack Trial (ALLHAT), one of the major studies showing 
equivalent efficacy of diuretics and other antihypertensives, 
was performed with chlorthalidone, which seems to be more 
effective than hydrochlorothiazide.41,42 Furthermore, hydro-
chlorothiazide at higher doses whereby its efficacy might be 
comparable with that of other antihypertensives, shows many 
adverse effects, including electrolyte imbalance (hypokalemia, 
hyponatremia), insulin resistance, and hyperuricemia, making 
it inappropriate as monotherapy.43 However, low-dose hydro-
chlorothiazide remains effective in lowering blood pressure, 
and from a pathophysiologic perspective, combines well with 
the RAAS inhibitors, including aliskiren.
Several trials have investigated the use of aliskiren and 
hydrochlorothiazide alone and in combination for treatment 
of hypertension (Table 2). In the largest trial to date, Villamil 
et al investigated the effects of aliskiren and hydrochlorothiaz-
ide in 2776 patients with mild hypertension and mean sitting 
diastolic blood pressure 95–109 mmHg. Aliskiren was used 
as monotherapy in doses of 75, 150, and 300 mg once daily, 
hydrochlorothiazide in doses of 6.25, 12.5, and 25 mg, and 
their combination included all possible doses except for the 
aliskiren-hydrochlorothiazide combination of 300/6.25 mg. 
The study was of double-blind, randomized, placebo-
controlled design and of eight weeks’ duration. Both drugs 
reduced blood pressure significantly compared with placebo, 
and interestingly, to the same extent for comparable doses of 
aliskiren and hydrochlorothiazide. Combination of the drugs 
lowered both diastolic and systolic blood pressure to a greater 
extent than either drug used alone. The response rates were 
also higher with the aliskiren-hydrochlorothiazide combina-
tion. Increased plasma renin activity and hypokalemia rates 
seen with hydrochlorothiazide monotherapy were reversed 
by addition of aliskiren, while the risk of hypokalemia in the 
combination groups was only slightly higher than with pla-
cebo.31 Post hoc analysis of the data showed that most of the 
dose combinations of aliskiren-hydrochlorothiazide were also 
superior to monotherapy in individuals with Stage 2 hyperten-
sion (mean sitting systolic blood pressure .160 mmHg).44
In a study of 489 obese hypertensive patients already 
treated with hydrochlorothiazide 25 mg, Jordan et al 
 examined the antihypertensive effects of the addition of 
aliskiren 300 mg, irbesartan 300 mg, or amlodipine 10 mg. 
The patients were unresponsive to previous monotherapy Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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with hydro  chlorothiazide. Addition of aliskiren led to a sig-
nificant reduction of blood pressure compared with a placebo-
  hydrochlorothiazide combination after eight weeks of treatment. 
Interestingly, the regimens including irbesartan 300 mg and 
amlodipine 10 mg had similar antihypertensive effects to those 
of the aliskiren-hydrochlorothiazide combination. However, 
the amlodipine-hydrochlorothiazide combination was less well 
tolerated as a result of an increased rate of peripheral edema. 
Plasma renin activity was, as expected, lower in the regimens 
including aliskiren, while the risk of hypokalemia was highest 
in the amlodipine-hydrochlorothiazide group.32
Aliskiren was compared with ramipril-based regimens in 
another study including 901 elderly (.65 years) hypertensive 
patients. Aliskiren at a starting dose of 150 mg and uptitrated to 
300 mg was compared with ramipril 5 mg uptitrated to 10 mg 
daily. If target blood pressure was not reached after 12 weeks, 
up to 25 mg of hydrochlorothiazide and, after 22 weeks, up to 
10 mg of amlodipine were added to both regimens. Regimens 
based on aliskiren led to higher rates of blood pressure control. 
At week 36, fewer patients on the aliskiren-based regimen 
required addon treatment with hydrochlorothiazide or amlo-
dipine compared with the ramipril regimens. Furthermore, 
lower rates of cough was reported for the aliskiren group.45
Two further studies have investigated single-pill com-
binations containing aliskiren. Nickenig et al examined 
  treatment with a combination of aliskiren-  hydrochlorothiazide 
300/12.5 mg or 300/25 mg in 880 hypertensive patients   
nonresponsive to aliskiren 300 mg alone (mean sitting diastolic 
blood pressure 90–110 mmHg after four weeks of treatment). 
Rates of blood pressure control were significantly higher 
using the single-pill regimens (60.2% for the 300/25 mg and 
57.9% for the 300/12.5 mg doses) than with aliskiren alone 
(40.9%). The tolerability of the single pill was similar to that of 
aliskiren alone.46 In another study, Blumenstein et al compared 
the single-pill combinations of aliskiren-hydrochlorothiazide 
150/25 mg and 300/25 mg with hydrochlorothiazide 25 mg 
monotherapy in 722 patients previously treated with hydro-
chlorothiazide 25 mg without having reached their target blood 
pressure. Both combinations were superior to hydrochloro-
thiazide monotherapy in reducing blood pressure. Fifty-eight 
percent of patients on the 300/25 mg combination reached their 
target blood pressure versus 49% for the 150/25 mg combina-
tion and 26% for hydrochlorothiazide 25 mg monotherapy. 
Tolerability was similar in all groups, although hypokalemia 
was higher in the hydrochlorothiazide monotherapy group.47
Safety and tolerability
It is important for a drug to be safe and well tolerated by 
patients. Overall, aliskiren in combination with hydro-
chlorothiazide was shown to be safe in various studies. 
Adverse effects were mild, and commonly included 
Table 2 Important studies comparing the effects of the aliskiren/hydrochlorothiazide combination with other treatment regimens
Reference Patients (n) Regimen Results
villamil31 2776 Ali 75-150-300
HCTZ 6.25-12.5-25
Ali-HCTZ all comb. except 300/6.25
Comparable doses of Ali and HCTZ  
equally effective in lowering BP, comb;  
achieved further BP reduction
Jordan32 489 obese pts already  
on HCTZ 25 mg
Ali-HCTZ 300/25
Irb-HCTZ 300/25
Aml-HCTZ 10/25
HCTZ 25
All combinations equally effective in 
lowering BP and better than HCTZ alone;   
Aml-HCTZ less tolerable due to edema, 
hypokalemia
Duprez45 901 elderly pts  
(.65 years)
Ali 150 → 300 
Ramipril 5 → 10
Add-on HCTZ 25 after 12 weeks 
and Aml 10 mg after 22 weeks, if needed
Ali group achieved target BP with the 
addition of fewer drugs
Strasser55 183 pts with severe hypertension  
(.180/110 mmHg)
Ali 150 → 300
Lis 20 → 40
Add-on HCTZ 25 as needed
Ali and Lis equally effective in lowering 
BP, HCTZ addon in similar number of pts  
in both groups needed
Nickenig46 880 pts unresponsive to  
Ali 300 alone
Single-pill Ali-HCTZ 300/12.5 or  
300/25 versus Ali 300 alone
Single-pill comb more effective in BP 
lowering than monotherapy, similarly well  
tolerated
Blumenstein47 722 pts unresponsive to  
HCTZ 25 alone
Single-pill Ali-HCTZ 150/25 or 300/25  
versus HCTZ 25 alone
Single-pill more efficient in lowering 
BP than monotherapy, similarly well 
tolerated, less hypokalemia with the 
single-pill combination
Note: Arrows indicate uptitration of the drug from the initial to the final dose.
Abbreviations: Ali, aliskiren; Aml, amlodipine; BP, blood pressure; HCTZ, hydrochlorothiazide; Irb, irbesartan; Lis, lisinopril; pts, patients.Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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headache (6% versus 9% with placebo), dizziness (2.5% 
versus 1% with placebo), diarrhea (1.8% versus 0.5% with 
placebo), and flu-like symptoms (2.5% versus 1.6% with 
placebo).31,32,40,46,48 Hypokalemia was significantly lower 
for the aliskiren-  hydrochlorothiazide combination (1%–2% 
in the combinations with hydrochlorothiazide 12.5 mg 
and 2%–3% in those with hydrochlorothiazide 25 mg) 
compared with hydrochlorothiazide alone (4%–5%) and 
slightly higher than in the placebo groups (1%) and for the 
irbesartan-  hydrochlorothiazide combination, especially in 
obese patients.31,32 Cough (1.5% versus 0.5% with placebo) 
presents less often than with ACE inhibitors and at a similar 
rate to that with ARBs.   Hyperkalemia might be of concern, 
especially when aliskiren is used in   conjunction with an 
ACE inhibitor or an ARB.
Cost comparison with other  
first-line treatments
An important aspect of antihypertensive drugs is their cost-
effectiveness. Aliskiren both alone and in combination 
with hydrochlorothiazide is able to reduce blood pressure 
to a   similar degree as ACE inhibitors and ARBs (and their 
combinations with hydrochlorothiazide). Treatment costs 
vary widely from country to country. However, the cost of 
aliskiren is similar to that of ARBs and much higher than that 
of the older ACE inhibitors. With ARBs and aliskiren being 
as effective in lowering blood pressure as the ACE   inhibitors 
and slightly better tolerated than the latter, treatment 
with an ACE inhibitor seems to be the logical first choice, 
with ARBs and aliskiren reserved for selected patients who 
cannot tolerate ACE inhibitors. Interestingly, aliskiren seems 
also to be as effective as hydrochlorothiazide and amlodipine, 
which are much cheaper treatment options. However, the 
tolerability of hydrochlorothiazide and amlodipine is inferior 
to that of aliskiren and they tend to have more side effects, 
including electrolyte disorders and edema.
Effects of aliskiren on cardiovascular 
disease outcomes
Of great importance is the effect of aliskiren on outcomes 
in patients with cardiovascular disease and end organ dam-
age. Several preclinical studies have demonstrated favor-
able effects of aliskiren on cardiac hypertrophy, myocardial 
function and remodeling after myocardial infarction, and 
kidney failure.49,50 However, there are no data available as 
yet showing a benefit of aliskiren in reducing cardiovascu-
lar mortality. Most studies have investigated the effects of 
aliskiren on biomarkers or surrogate outcomes, while large 
prospective trials with mortality outcomes are expected to 
be completed in the near future.
The ALiskiren Observation of Heart Failure Study 
(ALOFT) investigated the effects of add-on treatment with 
aliskiren 150 mg in 302 patients with stable heart failure 
(New York Heart Association II–IV) and hypertension, 
previously on ACE inhibitors or ARBs and beta-blockers.51 
Addon aliskiren therapy significantly reduced the levels of 
  N-terminal pro brain natriuretic peptide, without additional 
risk of hyperkalemia, hypotension, or worsening renal 
function. In the Aliskiren in Left Ventricular Hypertrophy 
(ALLAY) study, treatment with aliskiren 300 mg was 
noninferior to losartan 100 mg in reducing left ventricular 
hypertrophy.52 However, in the recently presented ASPIRE 
(Aliskiren Study in Post-MI Patients to Reduce   Remodeling) 
trial, aliskiren titrated to 300 mg on top of an ACE inhibitor 
or an ARB failed to show any improvement in myocardial 
remodeling after acute myocardial infarction and left ven-
tricular ejection fraction below 45%, while an increase in 
adverse effects was observed.53 In the AVOID trial (Aliskiren 
in the eValuation of prOteinuria in Diabetes), 599 hyperten-
sive diabetics with diabetic nephropathy and proteinuria were 
treated with aliskiren 300 mg or placebo on top of previous 
treatment with 100 mg losartan.54 Aliskiren reduced the 
albumin creatinine ratio by 20% compared with placebo after 
six months of treatment.
The findings of two large-scale trials, ie, ALTITUDE 
(Aliskiren Trial In Type 2 Diabetes Using Cardio-Renal 
Disease Endpoints) and ATMOSPHERE (Aliskiren Trial 
to Minimize OutcomeS in Patients with Heart FailuRE) are 
awaited with great interest. The aim of ALTITUDE is to 
examine whether aliskiren is able to reduce cardiovascular 
and renal morbidity and mortality when used on top of 
pre-existing therapy with an ACE inhibitor or an ARB in 
high-risk patients with Type 2 diabetes. ATMOSPHERE is 
investigating the effects of aliskiren on cardiovascular death 
and rehospitalization in patients with chronic heart failure.
Lessons from the  
ACCOMPLISH trial
ACE inhibitors and ARBs have been shown to reduce cardio-
vascular morbidity and mortality in many different patient 
groups and are considered first-line drugs in such patients. 
It is therefore intriguing to suggest, in expectation of large 
outcome trials, that aliskiren is also going to show similar 
results. However, cardiovascular patients tend to need more 
than one drug to control their hypertension. Therefore, it 
would be interesting to find an effective partner drug for Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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the RAAS inhibitors. Hydrochlorothiazide has been the 
standard add-on drug when monotherapy is inadequate. The 
recent ACCOMPLISH trial (Avoiding Cardiovascular Events 
in Combination Therapy in Patients Living with Systolic 
Hypertension) has shown that the combination of benazepril 
(an ACE inhibitor) and amlodipine prevents cardiovascular 
events more effectively than the combination of benazepril 
and hydrochlorothiazide. Therefore, one could speculate that 
amlodipine might be a more appropriate partner for aliskiren 
than hydrochlorothiazide in patients with hypertension and 
no signs of volume overload, where a diuretic would be more 
appropriate.
Conclusion
Only 30% of hypertensive patients reach target blood pres-
sure with monotherapy, and 70% require one or more addi-
tional agents. Fixed-drug combinations can improve patient 
compliance, and their use is supported by current guidelines 
for treatment of arterial hypertension. The combination of a 
RAAS inhibitor with hydrochlorothiazide is effective and 
reasonable because it potentiates the antihypertensive effects 
and lowers side effects of the component drugs. Aliskiren 
and its combination with hydrochlorothiazide appear to be 
as effective as ARBs and ACE inhibitors in the treatment of 
uncomplicated hypertension and as safe and tolerable as the 
ARBs and slightly better than the ACE inhibitors. However, 
there are still no clinical studies showing a mortality benefit 
for aliskiren or reduction of end organ damage, as are available 
for the ACE inhibitors and ARBs. Furthermore, the effects 
of reduced plasma renin activity and increased plasma renin 
concentration induced by aliskiren remain to be shown in large 
prospective studies and, while there are interesting experimen-
tal data, their clinical importance remains unclear.
Finally, it is intriguing to consider the findings of the 
recent ACCOMPLISH study and speculate that the combina-
tion of aliskiren with a calcium antagonist might be an even 
better combination, especially for patients with metabolic 
disorders and high cardiovascular risk.
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